Company name: Ube Industries, Ltd.
Representative: Hiroaki Tamura
President and Representative Director
Shares listed on: First Section of Tokyo Stock Exchange,
Fukuoka Stock Exchange
Security code number: 4208
Contact: Yasuko Sakamoto
General Manager, IR/PR Department
Tel: +81-3-5419-6110

European Commission Approves EFIENT™ (prasugrel) for Patients with Acute Coronary Syndrome Undergoing PCI

TOKYO, February 23, 2009 — Ube Industries, Ltd. today announced that the European Commission has granted marketing authorization for EFIENT™ (prasugrel) for the prevention of atherothrombotic events in patients with ACS undergoing percutaneous coronary intervention (PCI). This announcement by Ube Industries follows a separate joint press release issued by Daiichi Sankyo Co., Ltd. and Eli Lilly and Company.
Lilly, on behalf of its alliance partner, Daiichi Sankyo, submitted a New Drug Application for prasugrel to the U.S. Food and Drug Agency (FDA) in December 2007, and FDA's Cardiovascular and Renal Drugs Advisory Committee has issued an approval recommendation for prasugrel In February 3 (US Time).
From the above authorization, Ube Industries manufactures and supplies the bulk material of EFIENT™ which Daiichi Sankyo and Lilly anticipate its launch in each country of European Union in due course.

Prasugrel, an oral antiplatelet agent discovered by Ube Industries and Daiichi Sankyo, and co-developed in the global market by Daiichi Sankyo and Lilly works by inhibiting platelet activation and subsequent aggregation as a potential treatment, for patients with acute coronary syndromes who are undergoing PCI. Antiplatelet agents prevent platelets from clumping or sticking together, which can result in clogged arteries and may lead to heart attack or stroke. In a large Phase III study, prasugrel was superior to Plavix®/Iscover® (clopidogrel) in reducing the risk of suffering major cardiovascular events (combined endpoint of cardiovascular death, non-fatal heart attack or non-fatal stroke) in ACS patients undergoing PCI. The risk of non-coronary artery bypass graft (non-CABG) major bleeding, including fatal bleeding, was higher with prasugrel (2.2 percent incidence) compared with clopidogrel (1.7 percent incidence). Compared with the overall study population, a higher risk of serious bleeding among prasugrel patients was most evident in three distinct patient populations that are readily identifiable: patients who weighed less than 60 kg (132 lbs), patients who were 75 years of age or older and patients who have had a prior transient ischemic attack (TIA) or stroke. Patients who weighed less than 60 kg, or were 75 years of age or older had increased exposure with prasugrel.

Ube Industries earlier this year unveiled its Stage Up 2009 mid-term management plan, which identifies the Company's pharmaceuticals business as a developing business with future potential for growth and profitability.

Accordingly, Ube Industries is engaging in pharmaceuticals R&D with the goal of discovering new and proprietary pharmaceutical agents that will benefit society. Ube Industries co-developed the Talion® antiallergic agent with Tanabe Seiyaku Co., Ltd. (presently Mitsubishi Tanabe Pharma Corporation), and co-developed the Calblock® antihypertensive agent with Sankyo Co., Ltd. (presently Daiichi Sankyo). Talion® and Calblock® were approved and marketed in Japan in 2000 and 2003 respectively. Following these products, Ube Industries anticipates that this marketing authorization of prasugrel in Europe leads to the leap of our pharmaceuticals business.

- Efient™ is a trademark of Eli Lilly and Company.
- Plavix®/Iscover® are registered trademark of sanofi-aventis.
- Talion® is a registered trademark of Mitsubishi Tanabe Pharma Corporation.
- Calblock® is a registered trademark of Daiichi Sankyo Co., Ltd.

For inquiries please contact:
Ube Industries, Ltd.
Investor Relations & Public Relations Dept.
Corporate Planning & Administration Office
Seavans North Building, 1-2-1 Shibaura, Minato-ku, Tokyo 105-8449
Tel: +81(3)5419-6110